⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15577218 | 0.81 | — | — | |
| SCHEMBL27856745 | 0.79 | TDP1 (0.40) | — | |
| Bicarbonate SCHEMBL28121604 | 0.77 | KMT2A (0.34) | — | |
| SCHEMBL18985286 | 0.76 | TGM2 (0.40) | — | |
| SCHEMBL12700219 | 0.74 | ALDH1A1 (0.53) | — | |
| SCHEMBL28954592 | 0.74 | GAA (0.55) | — | |
| SCHEMBL6235734 | 0.72 | — | — | |
| SCHEMBL22648474 | 0.72 | SMN1; SMN2 (0.42) | — | |
| SCHEMBL27958193 | 0.71 | NPC1 (0.49) | — | |
| SCHEMBL27958195 | 0.71 | MAPT (0.62) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3484878-B1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-19 | — | — | EP | claimed |
| CN-101921268-A | 5-thiazole amide compound and biology application thereof | UNIV SUN YAT SEN CANCER CT | 2010-12-22 | — | — | CN | claimed |
| CN-101374824-A | Heterocyclic GABA-B modulators | ASTRAZENECA AB (SE) | 2009-02-25 | — | — | CN | claimed |
| US-20080312291-A1 | Heterocyclic Gaba-b Modulators | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | claimed |
| EP-1966176-A1 | HETEROCYCLIC GABA-B MODULATORS | AstraZeneca AB (SE) | 2008-09-10 | — | — | EP | claimed |
| WO-2007073296-A1 | HETEROCYCLIC GABA-B MODULATORS | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | claimed |
| EP-3484878-B1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-19 | — | — | EP | disclosed |
| CN-110437153-A | hepatitis B core protein allosteric modulators | UNIV INDIANA RES & TECH CORP | 2019-11-12 | — | — | CN | disclosed |
| CN-109970743-A | 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds as JAK inhibitors | 豪夫迈·罗氏有限公司 | 2019-07-05 | — | — | CN | disclosed |
| EP-3484878-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | Bristol-Myers Squibb Company (US) | 2019-05-22 | — | — | EP | disclosed |
| US-10183936-B2 | Hepatitis B core protein allosteric modulators | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-01-22 | — | — | US | disclosed |
| CN-104910161-B | Pyrazolopyrimidine compound and method as JAK inhibitor | 健泰科生物技术公司 | 2018-03-30 | — | — | CN | disclosed |
| WO-2018013774-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-18 | — | — | WO | disclosed |
| CN-101921268-A | 5-thiazole amide compound and biology application thereof | UNIV SUN YAT SEN CANCER CT | 2010-12-22 | — | — | CN | disclosed |
| CN-101641342-A | Thiazolidine derivatives | ACTELION PHARMACEUTICAL LTD CH | 2010-02-03 | — | — | CN | disclosed |
| CN-101374824-A | Heterocyclic GABA-B modulators | ASTRAZENECA AB (SE) | 2009-02-25 | — | — | CN | disclosed |
| US-20080312291-A1 | Heterocyclic Gaba-b Modulators | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| EP-1966176-A1 | HETEROCYCLIC GABA-B MODULATORS | AstraZeneca AB (SE) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007073296-A1 | HETEROCYCLIC GABA-B MODULATORS | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
| CN-1035753-A | Make cultivated plant avoid the thiazole-5-Carboxylamide of highy potent herbicide to the plant poisoning effect | CIBA GEIGY AG (CH) | 1989-09-27 | — | — | CN | disclosed |